



1H24 RESULTS RELEASE AND INVESTOR CALL

12 February 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX:MYX) announces that it will release its financial statements for the half year ended 31 December 2023 on Monday, 26 February 2024.

Mayne Pharma's CEO Mr Shawn Patrick O'Brien and CFO Mr Aaron Gray will host a webcast of the results at 9.00am AEDT on Monday 26 February 2024. Participants can register for the webcast by navigating to <https://s1.c-conf.com/diamondpass/10036603-7rd842.html>.

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

USA:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia